Protective Effect of CXCR3+CD4+CD25+Foxp3+ Regulatory T Cells in Renal Ischemia‐Reperfusion Injury

Cao, Jian; Li, Qingshu; Wei, Ke; Li, Ping; Dong, Jun; Luo, Jie; Min, Su

doi:10.1155/2015/360973

Cited by 25 publications

(30 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated that human peripheral CD4 + CD25 + Tregs can be accurately identified and purified using surface expression of CD127, as an alternative to the transcription factor FOXP3 (38)(39)(40)(41)(42)(43) + Tregs in the current study. A number of therapeutic approaches are aimed at inhibiting immune suppression within the tumor microenvironment.…”

Section: Discussionmentioning

confidence: 68%

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Wang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Previous studies have reported that regulatory T cells (Tregs), which are physiologically engaged in the maintenance of immunological self-tolerance, have a critical role in the regulation of the antitumor immune response. Targeting Tregs has the potential to augment cancer vaccine approaches. The current study therefore aimed to evaluate the role of cytokine-induced killer (CIK) cell infusion in modulating Tregs in patients with non-small cell lung cancer (NSCLC). A total of 15 patients with advanced NSCLC were treated by an infusion of CIK cells derived from autologous peripheral blood mononuclear cells (PBMCs). By using flow cytometry and liquid chip analysis, subsets of T cells and natural killer (NK) cells in peripheral blood, and plasma cytokine profiles in the treated patients, were analyzed at 2 and 4 weeks after CIK cell infusion. Cytotoxicity of PBMCs (n=15) and NK cells (n=6) isolated from NSCLC patients was evaluated before and after CIK cell therapy. Progression-free survival (PFS) and overall survival (OS) were also assessed. Analysis of the immune cell populations before and after treatment showed a significant increase in NK cells (P<0.05) concomitant with a significant decrease in Tregs (P<0.01) at 2 weeks post-infusion of CIK cells compared with the baseline. NK group 2D receptor (NKG2D) expression on NK cells was also significantly increased at 2 weeks post-infusion compared with the baseline (P<0.05). There was a positive correlation between NKG2D expression and the infusion number of CIK cells (P<0.05).

show abstract

Section: Discussionmentioning

confidence: 68%

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Wang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…low cells [64]. Similar to what occurs in humans, the use of this marker could also be controversial, as there is a subpopulation of activated CD4 1…”

Section: Cd25mentioning

confidence: 99%

Phenotypical characterization of regulatory T cells in humans and rodents

Rodríguez‐Perea

Arcia

Rueda

et al. 2016

Clinical and Experimental Immunology

142

122

View full text Add to dashboard Cite

SummaryRegulatory T cells (T regs ) constitute a fascinating subpopulation of CD4 1 T cells due to their ability to limit the immune response against self and non-self antigens. Murine models and antibodies directed against surface and intracellular molecules have allowed elucidation of the mechanisms that govern their development and function. However, these markers used to their classification lack of specificity, as they can be expressed by activated T cells. Similarly, there are slight differences between animal models, in steady state and pathological conditions, anatomical localization and strategy of analysis by flow cytometry. Here, we revised the most common markers utilized for T reg typification by flow cytometry such as CD25, forkhead box protein 3 (FoxP3) and CD127, along with our data obtained in different body compartments of humans, mice and rats. Furthermore, we revised and determined the expression of other molecules important for the phenotypical characterization of T reg cells. We draw attention to the drawbacks of those markers used in chronic states of inflammation. However, until a specific marker for the identification of T regs is discovered, the best combination of markers will depend upon the tissue or the degree of inflammation from which T regs derive.

show abstract

“…Tregs were observed to infiltrate in ischaemic-reperfused kidneys, which modulated pro-inflammatory cytokines production by other immune cells [14-17]. IL-10-producing Tregs were involved because the adoptive transfer of IL-10-deficient Tregs into Rag-1 knockout mice failed to recover renal function [15].…”

Section: Treg-mediated Repair At Multiple Tissuesmentioning

confidence: 99%

‘Repair’ Treg Cells in Tissue Injury

Zhang

Feng

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Studies in mice and humans have elucidated an important role for Tregs in promoting tissue repair and restoring tissue integrity. Emerging evidence has revealed that Tregs promoted wound healing and repair processes at multiple tissue sites, such as the heart, liver, kidney, muscle, lung, bone and central nervous system. The localization of repair Tregs in the lung, muscle and liver exhibited unique phenotypes and functions. Epidermal growth factor receptor, amphiregulin, CD73/CD39 and keratinocyte growth factor are important repair factors that are produced or expressed by repair Tregs; these factors coordinate with parenchymal cells to limit injury and promote repair. In addition, repair Tregs can be modulated by IL-33/ST2, TCR signals and other cytokines in the context of injured microenvironment cues. In this review, we provide an overview of the emerging knowledge about Treg-mediated repair in damaged tissues and organs.

show abstract

Protective Effect of CXCR3⁺CD4⁺CD25⁺Foxp3⁺ Regulatory T Cells in Renal Ischemia‐Reperfusion Injury

Cited by 25 publications

References 30 publications

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Phenotypical characterization of regulatory T cells in humans and rodents

‘Repair’ Treg Cells in Tissue Injury

Contact Info

Product

Resources

About